Clinical Trial of Pioglitazone for Prevention of Cardiac Allograft Vasculopathy After Heart Transplantation

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Kiran Khush, Stanford University
ClinicalTrials.gov Identifier:
NCT01186250
First received: August 19, 2010
Last updated: July 8, 2016
Last verified: July 2016

August 19, 2010
July 8, 2016
July 2010
August 2013   (final data collection date for primary outcome measure)
Insulin Levels Area Under Curve(AUC) [ Time Frame: Baseline and 1 year ] [ Designated as safety issue: No ]
Change from baseline in Insulin Levels During Oral Glucose Tolerance test at 1 year.
Insulin levels during oral glucose tolerance test [ Time Frame: Baseline and 1 year ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01186250 on ClinicalTrials.gov Archive Site
  • Change in Intimal Volume [ Time Frame: baseline and 1 year ] [ Designated as safety issue: No ]
    Intimal volume is defined as external elastic membrane volume minus lumen (luminal) volume measured at the heart Catheterization and intravascular Ultrasound( IVUS)
  • Change in Levels of Fasting Glucose at Baseline and 1 Year [ Time Frame: Baseline and 1 year ] [ Designated as safety issue: No ]
    Oral Glucose Tolerance Test : blood was drawn for fasting plasma glucose and insulin levels, followed by ingestion of a solution containing 75grams of glucose. Repeat blood samples were collected for glucose and insulin levels at 30, 90, and 120 minutes after glucose ingestion. All glucose measurements were performed by the Clinical Translational Research Unit (CTRU) Stanford University.
  • Change From Baseline in TG/HDL Ratio at One Year [ Time Frame: Baseline and 1 year ] [ Designated as safety issue: No ]
    Triglyceride ratio to High Density Lipoprotien
  • Change in Maximal Intimal Thickness(MIT) by Intravascular Unltrasound(IVUS) [ Time Frame: Baseline and 1 year ] [ Designated as safety issue: No ]
    The change in maximal intimal thickness (MIT) from baseline to one year was recorded for several matched sites in the same coronary artery, the cross sections, predominantly in the left anterior descending coronary artery, from baseline to one-year follow-up, were studied. The IVUS cross sections were matched by using identifiable landmarks in the images, such as bifurcations or arterial calcification, or external landmarks, such as coronary veins or pericardium. In addition, the one-year IVUS studies were obtained with an angiographic roadmap of where the initial IVUS study was performed along the length of the vessel. The IVUS system auto pullback was performed at .5 mm/s from the mid-distal portion of the study vessel, where an easily identifiable landmark was visible (i.e., branchpoint). The following items were measured for each patient: maximal intimal thickness (MIT), intimal area (IA), and vessel area.
  • Change From Baseline in ADMA (Asymmetric Dimethylarginine) at One Year. [ Time Frame: Baseline and 1 year ] [ Designated as safety issue: No ]
    Competitive ELISA assay in Stanford laboratory.
  • Change From Baseline in High-sensitivity C-reactive Protein (HsCRP) at One Year [ Time Frame: Baseline and 1 year ] [ Designated as safety issue: No ]
    measure of low levels of C-reactive protein to identify low but persistent levels of inflammation
  • mean coronary artery plaque volume [ Time Frame: baseline and 1 year ] [ Designated as safety issue: No ]
  • Change in levels of fasting glucose, lipids, ADMA, and hs-CRP [ Time Frame: Baseline and 1 year ] [ Designated as safety issue: No ]
  • Change in levels of circulating markers of inflammation [ Time Frame: Baseline and 1 year ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Clinical Trial of Pioglitazone for Prevention of Cardiac Allograft Vasculopathy After Heart Transplantation
Clinical Trial of Pioglitazone for Prevention of Cardiac Allograft Vasculopathy After Heart Transplantation
The purpose of this study is to determine the benefit of using the FDA-approved insulin-sensitizing agent, Pioglitazone, on human heart transplant recipients. The objectives of this project are to (1) determine if pioglitazone effectively treats insulin resistance in heart transplant recipients, and (2) to determine whether pioglitazone therapy after heart transplantation impacts the development or progression of cardiac allograft vasculopathy (CAV), a form of chronic rejection after heart transplantation.
CAV, a rapidly progressive obliterative disease involving the graft coronary arteries, is the leading cause of morbidity and mortality beyond the first year after heart transplantation. This common complication occurs in almost half of recipients within 3 years after heart transplantation, and is associated with high rates of graft failure and mortality. Clinical care of heart transplant recipients in the current era is greatly limited by the lack of effective treatment options to prevent or retard the progression of CAV. CAV appears to be strongly associated with the state of insulin resistance, which is present in over half of heart transplant recipients and is characterized by metabolic abnormalities including glucose intolerance, dyslipidemia, endothelial dysfunction, and high levels of circulating inflammatory markers. Insulin resistance can be effectively treated with pioglitazone, a TZD compound which directly affects tissue insulin sensitivity. In this study, we will enroll 32 insulin-resistant heart transplant recipients and will randomize them to pioglitazone or placebo for a one-year period. We will determine the efficacy of pioglitazone for the treatment of insulin resistance and prevention of the development and progression of CAV after heart transplantation. The data generated from this study will provide important preliminary data for future, larger-scale clinical investigations.
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Cardiac Allograft Vasculopathy
  • Drug: Pioglitazone
    15mg pioglitazone taken daily for one month, 30mg pioglitazone taken daily for another month, 45mg pioglitazone taken daily for remaining ten months
    Other Name: Actos
  • Drug: Placebo
    placebo taken daily for one year
  • Active Comparator: Pioglitazone
    Pioglitazone
    Intervention: Drug: Pioglitazone
  • Placebo Comparator: Placebo
    Placebo
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
18
December 2013
August 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Heart transplant recipients, years 1-4 post-transplant
  2. Age >= 18 years
  3. Fasting TG/HDL ratio>=3.0 or Fasting TG>=150 mg/dL

Exclusion Criteria:

  1. Diabetes mellitus
  2. Severe liver dysfunction (ALT>=2.5 x upper limit of normal)
  3. Severe renal dysfunction (GFR<30 or Stage IV CKD)
  4. Moderate-severe fluid retention
  5. Clinical or echocardiographic signs of left ventricular dysfunction
  6. Contraindication to coronary angiography and/or IVUS
Both
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01186250
SU-05282010-6202, CTRU protocol 1314, IRB protocol 19373
Yes
Not Provided
Not Provided
Kiran Khush, Stanford University
Stanford University
Not Provided
Principal Investigator: Kiran Khush Stanford University
Stanford University
July 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP